Diego Santos-García1, Teresa de Deus2, Carlos Cores1, Hector Canfield2, Jose M Paz González1, Cristina Martínez Miró1, Lorena Valdés Aymerich1, Ester Suárez2, Silvia Jesús3,4, Miquel Aguilar5, Pau Pastor5, Lluis Planellas6, Marina Cosgaya6, Juan García Caldentey7, Nuria Caballol8, Ines Legarda9, Jorge Hernández-Vara10, Iria Cabo11, Lydia López Manzanares12, Isabel González Aramburu4,13, Maria A Ávila Rivera14, Maria J Catalán15, Victor Nogueira16, Victor Puente17, Julio Dotor18, Carmen Borrué19, Berta Solano20, Maria Álvarez Sauco21, Lydia Vela22, Sonia Escalante23, Esther Cubo24, Francisco Carrillo25, Juan C Martínez Castrillo26, Pilar Sánchez Alonso27, Gemma Alonso28, Nuria López Ariztegui29, Itziar Gastón30, Jaime Kulisevsky4,31, Marta Blázquez32, Manuel Seijo11, Javier Rúiz Martínez33, Caridad Valero34, Monica Kurtis35, Oriol de Fábregues10, Jessica Ardura36, Ruben Alonso37, Carlos Ordás38, Luis M López Díaz39, Darrian McAfee40, Pablo Martinez-Martin4, Pablo Mir3,4. 1. CHUAC, Complejo Hospitalario Universitario de A Coruña, 15006 A Coruña, Spain. 2. CHUF, Complejo Hospitalario Universitario de Ferrol, 15405 A Coruña, Spain. 3. Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41009 Seville, Spain. 4. CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), 28031 Madrid, Spain. 5. Hospital Universitari Mutua de Terrassa, 08221 Barcelona, Spain. 6. Hospital Clínic de Barcelona, 08036 Barcelona, Spain. 7. Centro Neurológico Oms 42, 07003 Palma de Mallorca, Spain. 8. Consorci Sanitari Integral, Hospital Moisés Broggi, 08970 Barcelona, Spain. 9. Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain. 10. Hospital Universitario Vall d'Hebron, 08035 Barcelona, Spain. 11. Complejo Hospitalario Universitario de Pontevedra (CHOP), 36071 Pontevedra, Spain. 12. Hospital Universitario La Princesa, 28006 Madrid, Spain. 13. Hospital Universitario Marqués de Valdecilla, 39011 Santander, Spain. 14. Consorci Sanitari Integral, Hospital General de L'Hospitalet, 08906 Barcelona, Spain. 15. Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain. 16. Hospital Da Costa, 27880 Burela, Spain. 17. Hospital del Mar, 08003 Barcelona, Spain. 18. Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain. 19. Hospital Infanta Sofía, 28702 Madrid, Spain. 20. Institut d'Assistència Sanitària (IAS)-Institut Català de la Salut, 17190 Girona, Spain. 21. Hospital General Universitario de Elche, 03203 Elche, Spain. 22. Fundación Hospital de Alcorcón, 28922 Madrid, Spain. 23. Hospital de Tortosa Verge de la Cinta (HTVC), 43500 Tarragona, Spain. 24. Complejo Asistencial Universitario de Burgos, 09006 Burgos, Spain. 25. Hospital Universitario de Canarias, 38320 San Cristóbal de la Laguna, Spain. 26. Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain. 27. Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain. 28. Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), 36213 Vigo, Spain. 29. Complejo Hospitalario de Toledo, 45071 Toledo, Spain. 30. Complejo Hospitalario de Navarra, 31008 Pamplona, Spain. 31. Hospital de Sant Pau, 08041 Barcelona, Spain. 32. Hospital Universitario Central de Asturias, 33011 Oviedo, Spain. 33. Hospital Universitario Donostia, 20009 San Sebastián, Spain. 34. Hospital Arnau de Vilanova, 46015 Valencia, Spain. 35. Hospital Ruber Internacional, 28034 Madrid, Spain. 36. Hospital de Cabueñes, 33394 Gijón, Spain. 37. Hospital Universitario Lucus Augusti (HULA), 27002 Lugo, Spain. 38. Hospital Rey Juan Carlos, 28933 Madrid, Spain. 39. Complejo Hospitalario Universitario de Orense (CHUO), 32005 Orense, Spain. 40. Laboratory for Cognition and Neural Stimulation, Univeristy of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract
Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson's disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = -0.52), change from V0 to V2 in PDSS (Parkinson's Disease Sleep Scale) (β = -0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.
Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson's disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods:PDpatients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PDpatients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = -0.52), change from V0 to V2 in PDSS (Parkinson's Disease Sleep Scale) (β = -0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PDpatients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.
Entities:
Keywords:
Parkinson’s disease; mood; non-motor symptoms; progression; quality of life
Authors: R Erro; M Picillo; C Vitale; M Amboni; M Moccia; G Santangelo; M T Pellecchia; P Barone Journal: Eur J Neurol Date: 2016-07-20 Impact factor: 6.089
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira Journal: Mov Disord Date: 2007-10-15 Impact factor: 10.338
Authors: D Santos García; S Jesús; M Aguilar; L L Planellas; J García Caldentey; N Caballol; I Legarda; J Hernández Vara; I Cabo; L López Manzanares; I González Aramburu; M A Ávila Rivera; M J Catalán; L López Díaz; V Puente; J M García Moreno; C Borrué; B Solano Vila; M Álvarez Sauco; L Vela; S Escalante; E Cubo; F Carrillo Padilla; J C Martínez Castrillo; P Sánchez Alonso; M G Alonso Losada; N López Ariztegui; I Gastón; J Kulisevsky; M Menéndez González; M Seijo; J Rúiz Martínez; C Valero; M Kurtis; O de Fábregues-Boixar; J González Ardura; C Prieto Jurczynska; P Martinez-Martin; P Mir Journal: Eur J Neurol Date: 2019-07-04 Impact factor: 6.089
Authors: Kallol Ray Chaudhuri; Jose Manuel Rojo; Anthony H V Schapira; David J Brooks; Fabrizio Stocchi; Per Odin; Angelo Antonini; Richard G Brown; Richard J Brown; Pablo Martinez-Martin Journal: PLoS One Date: 2013-02-27 Impact factor: 3.240
Authors: Diego Santos-García; Teresa de Deus Fonticoba; Carlos Cores Bartolomé; Maria J Feal Painceiras; Ester Suárez Castro; Héctor Canfield; Cristina Martínez Miró; Silvia Jesús; Miquel Aguilar; Pau Pastor; Lluís Planellas; Marina Cosgaya; Juan García Caldentey; Nuria Caballol; Ines Legarda; Jorge Hernández-Vara; Iria Cabo; Lydia López Manzanares; Isabel González Aramburu; Maria A Ávila Rivera; Víctor Gómez Mayordomo; Víctor Nogueira; Víctor Puente; Julio Dotor García-Soto; Carmen Borrué; Berta Solano Vila; María Álvarez Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo Padilla; Juan C Martínez Castrillo; Pilar Sánchez Alonso; Maria G Alonso Losada; Nuria López Ariztegui; Itziar Gastón; Jaime Kulisevsky; Marta Blázquez Estrada; Manuel Seijo; Javier Rúiz Martínez; Caridad Valero; Mónica Kurtis; Oriol de Fábregues; Jessica González Ardura; Ruben Alonso Redondo; Carlos Ordás; Luis M López Díaz; Darrian McAfee; Pablo Martinez-Martin; Pablo Mir Journal: Diagnostics (Basel) Date: 2022-05-05
Authors: Diego Santos García; Gustavo Fernández Pajarín; Juan Manuel Oropesa-Ruiz; Francisco Escamilla Sevilla; Raúl Rashid Abdul Rahim López; José Guillermo Muñoz Enríquez Journal: Brain Sci Date: 2022-03-12